Your browser doesn't support javascript.
loading
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
Tucker, Douglass W; Getchell, Christopher R; McCarthy, Eric T; Ohman, Anders W; Sasamoto, Naoko; Xu, Shuyun; Ko, Joo Yeon; Gupta, Mamta; Shafrir, Amy; Medina, Jamie E; Lee, Jonathan J; MacDonald, Lauren A; Malik, Ammara; Hasselblatt, Kathleen T; Li, Wenjing; Zhang, Hong; Kaplan, Samuel J; Murphy, George F; Hirsch, Michelle S; Liu, Joyce F; Matulonis, Ursula A; Terry, Kathryn L; Lian, Christine G; Dinulescu, Daniela M.
Afiliação
  • Tucker DW; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Getchell CR; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • McCarthy ET; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ohman AW; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Sasamoto N; Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Xu S; Department of Pathology, Division of Dermatopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ko JY; Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea.
  • Gupta M; Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Shafrir A; Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Medina JE; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Lee JJ; Department of Pathology, Division of Dermatopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • MacDonald LA; Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts.
  • Malik A; Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts.
  • Hasselblatt KT; Gynecologic Oncology Laboratory, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Li W; Department of Medicine, Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts.
  • Zhang H; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Kaplan SJ; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Murphy GF; Department of Pathology, Division of Dermatopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Hirsch MS; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts.
  • Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts.
  • Terry KL; Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ddinulescu@bwh.harvard.edu cglian@bwh.harvard.edu kterry@bwh.harvard.edu.
  • Lian CG; Department of Pathology, Division of Dermatopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ddinulescu@bwh.harvard.edu cglian@bwh.harvard.edu kterry@bwh.harvard.edu.
  • Dinulescu DM; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ddinulescu@bwh.harvard.edu cglian@bwh.harvard.edu kterry@bwh.harvard.edu.
Clin Cancer Res ; 24(6): 1389-1401, 2018 03 15.
Article em En | MEDLINE | ID: mdl-29263182
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cistadenocarcinoma Seroso / 5-Metilcitosina / Epigênese Genética / Reprogramação Celular Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cistadenocarcinoma Seroso / 5-Metilcitosina / Epigênese Genética / Reprogramação Celular Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article